Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 17/20 | 0.66 |
| ▸ | CA12 | O43570 | 13/20 | 0.66 |
| ▸ | CA9 | Q16790 | 13/20 | 0.66 |
| ▸ | CA2 | P00918 | 16/20 | 0.62 |
| ▸ | CA4 | P22748 | 2/20 | 0.62 |
| ▸ | CA7 | P43166 | 2/20 | 0.62 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.51 |
| ▸ | KDR | P35968 | 1/20 | 0.50 |
| ▸ | TGM2 | P21980 | 1/20 | 0.47 |
| ▸ | CES1 | P23141 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5427496 | 0.91 | CA1 (0.54) | CA1CA12CA9CA2CA4 | |
| SCHEMBL5427493 | 0.91 | CA1 (0.54) | CA1CA12CA9CA2CA4 | |
| SCHEMBL5183261 | 0.90 | CA1 (0.58) | CA1CA12CA9CA2CA4 | |
| SCHEMBL5419122 | 0.90 | CA1 (0.58) | CA1CA12CA9CA2CA4 | |
| SCHEMBL5425595 | 0.88 | CA1 (0.52) | CA1CA12CA9CA2CA4 | |
| SCHEMBL5168743 | 0.88 | CA1 (0.54) | CA1CA12CA9CA2CA4 | |
| SCHEMBL5427735 | 0.88 | CA1 (0.54) | CA1CA12CA9CA2CA4 | |
| SCHEMBL5425596 | 0.88 | CA1 (0.52) | CA1CA12CA9CA2CA4 | |
| Gw280670X SCHEMBL14040830 | 0.87 | CA1 (0.70) | CA1CA12CA9CA2CA4 | |
| SCHEMBL6620150 | 0.87 | CA1 (0.54) | CA1CA12CA9CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180127365-A1 | C5, C6 SUBSTITUTED AND/OR FUSED OXINDOLES AS ANTI-CANCER AGENTS AND PROCESS FOR PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2018-05-10 | — | — | US | disclosed |
| US-20180000771-A1 | AGENT FOR PREVENTING AND/OR TREATING AMYOTROPHIC LATERAL SCLEROSIS | KYOTO UNIVERSITY (JP) | 2018-01-04 | — | — | US | disclosed |
| US-8778643-B2 | Methods for increasing lipid levels and producing triacylglycerols in algae | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-07-15 | — | — | US | disclosed |
| US-8778643-B2 | Methods for increasing lipid levels and producing triacylglycerols in algae | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-07-15 | — | — | US | disclosed |
| US-20130273620-A1 | METHODS FOR ALTERING LIPIDS IN ALGAE AND YEAST | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2013-10-17 | — | — | US | disclosed |
| US-20130273620-A1 | METHODS FOR ALTERING LIPIDS IN ALGAE AND YEAST | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2013-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180000771-A1 | AGENT FOR PREVENTING AND/OR TREATING AMYOTROPHIC LATERAL SCLEROSIS | WEE2, WEE1, ERBB2 | CA1 4381/4885CA12 4753/4885CA9 4597/4885 |
| US-20180127365-A1 | C5, C6 SUBSTITUTED AND/OR FUSED OXINDOLES AS ANTI-CANCER AGENTS AND PROCESS FOR PREPARATION THEREOF | CCNH, C5, CCNI | CA1 2082/4885CA12 1710/4885CA9 639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.